Table 2.
Incidence rates per 1000 person-years.
| Number of events, n (%) | Moderate-to-severe disease | Mild disease n = 822,906 |
|||||
|---|---|---|---|---|---|---|---|
| Biologic n = 1817 |
Methotrexate n = 1153 |
Cyclosporine n = 755 |
Mixed conventional systemic n = 679 |
Phototherapy n = 83,838 |
|||
| Composite endpoint including all-cause mortality (MACE) | 19 (1.0) | 41 (3.6) | 61 (8.1) | 75 (11.0) | 2300 (2.7) | 34,914 (4.2) | |
| Mortalitya | 8 (0.4) | 28 (2.4) | 44 (5.8) | 44 (6.5) | 997 (1.2) | 14,345 (1.7) | |
| Composite endpoint excluding all-cause mortality (Only CV) | 11 (0.6) | 13 (1.1) | 17 (2.3) | 31 (4.6) | 1303 (1.6) | 20,569 (2.5) | |
| Coronary arterial disease | 0 | 0 | 0 | 0 | 44 (0.1) | 738 (0.1) | |
| Total strokeb | 10 (0.6) | 13 (1.1) | 16 (2.1) | 29 (4.3) | 1165 (1.4) | 18,794 (2.3) | |
| Ischemic stroke | 8 (0.4) | 8 (0.7) | 16 (2.1) | 23 (3.4) | 894 (1.1) | 15,204 (1.8) | |
| Hemorrhagic stroke | 1 (0.1) | 5 (0.4) | 0 | 6 (0.9) | 192 (0.2) | 2512 (0.3) | |
| Cardiac arrest | 1 (0.1) | 0 | 1 (0.1) | 2 (0.3) | 94 (0.1) | 1037 (0.1) | |
| Incidence rate per 1000 person-year | |||||||
| MACE | 3.5 | 12.1 | 28.4 | 39.5 | 9.3 | 14.5 | |
| Only CV | 2.0 | 3.8 | 7.6 | 15.6 | 5.2 | 8.4 | |
| Incidence rate per 1000 person-year for age groups | |||||||
| Aged ≤ 40 | MACE | 1.8 | 1.8 | 6.2 | 7.7 | 1.7 | 1.7 |
| Only CV | 1.2 | 0 | 3.1 | 3.0 | 0.8 | 0.9 | |
| Aged 41—60 | MACE | 4.5 | 7.6 | 26.7 | 30.0 | 9.8 | 9.5 |
| Only CV | 2.2 | 1.7 | 2.3 | 12.1 | 5.9 | 6.2 | |
| Aged ≥ 61 | MACE | 20.5 | 56.2 | 90.8 | 103.3 | 46.1 | 48.8 |
| Only CV | 12.1 | 20.1 | 30.2 | 38.0 | 25.1 | 26.8 | |
CV, cardiovascular; MACE, major adverse cardiovascular events.
aClassified as “other CV event” when death and CV disease occurred simultaneously on the same day.
bIncludes strokes not associated with ischemic and hemorrhagic causes.